RE-BVS – Piemonte Repository

Sfoglia per AUTORE
EGYED M
Collezione AOU Città della Salute di Torino

Items : 3

The Association between Patient Characteristics and the Efficacy and Safety of Selinexor in Diffuse Large B-Cell Lymphoma in the SADAL Study. in Cancers / Cancers (Basel). 2022 Feb 4;14(3):791. doi: 10.3390/cancers14030791.

2022
AOU Città della Salute di Torino

Zijlstra JM; Follows G; Casasnovas RO; Vermaat JSP; Kalakonda N; Choquet S; Hill B; Thieblemont C; Cavallo F; Cruz F; Kuruvilla J; Hamad N; Jaeger U; Caimi P; Gurion R; Warzocha K; Bakhshi S; Sancho JM; Schuster M; Egyed M; Offner F; Vassilakopoulos TP; Samal P; Ku M; Xu J; Corona K; Chamoun K; Shah J; Canales M; et alii...

Ruxolitinib for the treatment of inadequately controlled polycythemia vera without splenomegaly: 80-week follow-up from the RESPONSE-2 trial. in Annals of hematology / Ann Hematol. 2018 Sep;97(9):1591-1600. doi: 10.1007/s00277-018-3365-y. Epub 2018 May 27.

2018
AOU Città della Salute di Torino

Bensasson C; Guglielmelli P; Sivgin S; Devos T; Callum J; Egyed M; Palandri F; Benevolo G; Saydam G; Griesshammer M; Khan M; Ronco JP; Passamonti F; Griesshammer M; Saydam G; Palandri F; Benevolo G; Egyed M; Callum J; Devos T; Sivgin S; Guglielmelli P; Bensasson C; Khan M; Ronco JP; Passamonti F;

Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study. in The Lancet. Oncology / Lancet Oncol. 2017 Jan;18(1):88-99. doi: 10.1016/S1470-2045(16)30558-7. Epub 2016 Dec 2.

2017
AOU Città della Salute di Torino

Bensasson C; Sivgin S; Vannucchi AM; Callum J; Devos T; Egyed M; Benevolo G; Palandri F; Griesshammer M; Passamonti F; Khan M; Mounedji N; Saydam G;